The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma

Table 1

Clinicopathological characteristics of melanoma patients from TCGA database.

Characteristics		Training cohort; ()		Validation cohort; ()
	Groups	No.	%	No.	%	value
Gender	Male	185	64.0	89	61.4	0.592
	Female	104	36.0	56	38.6
Age at diagnosis	<50	89	30.8	44	30.4	0.898
	50-70	132	45.7	64	44.1
	>70	68	23.5	37	25.5
Race	White	274	94.8	138	95.2	0.871
	Others/unknown	15	5.2	7	4.8
Breslow depth	<2	80	27.7	46	31.7	0.658
	2-5	79	27.3	34	23.4
	>5	59	20.4	33	22.8
	Unknown	71	24.6	32	22.1
Clark level	I-II	17	5.9	6	4.1	0.491
	III-IV	151	52.2	80	55.2
	V	28	9.7	19	13.1
	Unknown	93	32.2	40	27.6
Pathologic T	T0-T2	82	28.4	57	39.3	0.342
	T3-T4	149	51.5	68	46.9
	Unknown	58	20.1	20	13.8
Pathologic N	N0	142	49.1	74	51.0	0.719
	N1	48	16.6	23	15.9
	N2	28	9.7	19	13.1
	N3	37	12.8	16	11.0
	Unknown	34	11.8	13	9.0
Pathologic M	M0	257	88.9	128	88.3	0.476
	M1	17	5.9	6	4.1
	Unknown	15	5.2	11	7.6
Pathologic stage	0	5	1.8	1	0.7	0.651
	I	46	15.9	30	20.7
	II	80	27.7	41	28.3
	III	109	37.7	55	37.9
	IV	16	5.5	6	4.1
	Unknown	33	11.4	12	8.3
Tumor location	Primary tumor	52	18.0	26	17.9	0.592
	Regional cutaneous or Subcutaneous tissue	46	15.9	27	18.6
	Regional lymph node	142	49.2	74	51.1
	Distant metastasis	46	15.9	18	12.4
	Unknown	3	1.0	0	0
Anatomic site	Extremities	129	44.6	58	40.0	0.792
	Head and neck	20	6.9	12	8.3
	Trunk	100	34.6	52	35.9
	Others/unknown	40	13.9	23	15.8